Patents by Inventor Michael Looby

Michael Looby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20250262171
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: September 27, 2024
    Publication date: August 21, 2025
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20220142949
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: September 20, 2021
    Publication date: May 12, 2022
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20200330407
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20190091180
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20180289638
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20170189353
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20160263061
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Applicant: Novartis AG
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20160081949
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: December 2, 2015
    Publication date: March 24, 2016
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20140148415
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: NOVARTIS AG
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20140066657
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage
    Type: Application
    Filed: September 6, 2013
    Publication date: March 6, 2014
    Applicant: Novartis AG
    Inventors: Robert Schmouder, Thomas Dumortier, Olivier David, Michael Looby
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20110257133
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 20, 2011
    Inventors: Robert Schmouder, Thomas Dumortier, Olivier David, Michael Looby
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20100160259
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage
    Type: Application
    Filed: December 21, 2009
    Publication date: June 24, 2010
    Inventors: Robert Schmouder, Thomas Dumortier, Olivier David, Michael Looby
  • Pharmaceutical combinations
    Publication number: 20020098179
    Abstract: This invention relates, inter alia, to methods of treating pathophysiological conditions involving neutrophils, comprising administering to a patient in need of such treatment a combination therapy comprising at least one Neutrophil Inhibitory Factor (NIF) and at least one other agent that protects neurons from toxic insult, inhibits the inflammatory reaction after brain damage or promotes cerebral reperfusion (i.e. neuroprotective or thrombolytic/fibrinolytic agents), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 1, 2001
    Publication date: July 25, 2002
    Inventors: Christopher John Brearley, Paul Butler, Suresh Babubhai Chahwala, Michael Chopp, Michael Krams, Michael Looby, Fiona MacIntyre, Andrew Brian McElroy, Aileen Dorothy McHarg